News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CLOTS 3 Study Delivers Lifesaving Results Using Covidien plc (COV)'s Blood Clot Prevention Technology



6/20/2013 9:35:07 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MANSFIELD, Mass.--(BUSINESS WIRE)--Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that an independent study conducted by the University of Edinburgh has successfully demonstrated the effectiveness of Covidien’s Kendall SCD™ system with Vascular Refill Detection Technology on immobile stroke patients. The results of the CLOTS 3 trial were presented at the European Stroke Conference by Professor Martin S. Dennis of the University of Edinburgh’s Division of Clinical Neurosciences and also published in The Lancet. The new study showed a 29.9% decrease in the development of proximal deep vein thrombosis (DVT) in immobile stroke patients who received intermittent pneumatic compression (IPC) using the Kendall SCD system with Vascular Refill Detection Technology, which delivers sequential, circumferential, gradient compression through thigh-length sleeves. Compared to the routine care group only, the IPC group also showed a 14% mortality risk reduction (p = 0.042) during the first six months after hospital admission for stroke.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES